EE200100528A - Asendatud bitsükliline heteroarüülühend, seda sisaldav farmatseutiline kompositsioon ning nende raviotstarbeline kasutamine - Google Patents

Asendatud bitsükliline heteroarüülühend, seda sisaldav farmatseutiline kompositsioon ning nende raviotstarbeline kasutamine

Info

Publication number
EE200100528A
EE200100528A EEP200100528A EEP200100528A EE200100528A EE 200100528 A EE200100528 A EE 200100528A EE P200100528 A EEP200100528 A EE P200100528A EE P200100528 A EEP200100528 A EE P200100528A EE 200100528 A EE200100528 A EE 200100528A
Authority
EE
Estonia
Prior art keywords
linkage
optionally substituted
direct bond
compounds
alkylene
Prior art date
Application number
EEP200100528A
Other languages
English (en)
Estonian (et)
Inventor
Edward Clark David
Robert Eastwood Paul
Victor Harris Neil
Mccarthy Clive
David Morley Andrew
Dennis Pickett Stephen
Original Assignee
Aventis Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9908355.2A external-priority patent/GB9908355D0/en
Application filed by Aventis Pharma Limited filed Critical Aventis Pharma Limited
Publication of EE200100528A publication Critical patent/EE200100528A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EEP200100528A 1999-04-12 2000-04-12 Asendatud bitsükliline heteroarüülühend, seda sisaldav farmatseutiline kompositsioon ning nende raviotstarbeline kasutamine EE200100528A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9908355.2A GB9908355D0 (en) 1999-04-12 1999-04-12 Chemical compounds
US14147099P 1999-06-29 1999-06-29
PCT/GB2000/001393 WO2000061580A1 (en) 1999-04-12 2000-04-12 Substituted bicyclic heteroaryl compounds as integrin antagonists

Publications (1)

Publication Number Publication Date
EE200100528A true EE200100528A (et) 2003-02-17

Family

ID=26315408

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100528A EE200100528A (et) 1999-04-12 2000-04-12 Asendatud bitsükliline heteroarüülühend, seda sisaldav farmatseutiline kompositsioon ning nende raviotstarbeline kasutamine

Country Status (24)

Country Link
US (1) US6706738B2 (de)
EP (1) EP1183254B1 (de)
KR (1) KR20010110750A (de)
CN (1) CN1350534A (de)
AT (1) ATE286896T1 (de)
AU (1) AU769554B2 (de)
BG (1) BG106083A (de)
BR (1) BR0010599A (de)
CA (1) CA2369728A1 (de)
CZ (1) CZ20013661A3 (de)
DE (1) DE60017389T2 (de)
EE (1) EE200100528A (de)
ES (1) ES2231179T3 (de)
HK (1) HK1044937A1 (de)
HR (1) HRP20010732A2 (de)
HU (1) HUP0200803A3 (de)
IL (2) IL145748A0 (de)
MX (1) MXPA01010231A (de)
NO (1) NO20014951L (de)
NZ (1) NZ514602A (de)
PL (1) PL351433A1 (de)
SK (1) SK14372001A3 (de)
TR (1) TR200102959T2 (de)
WO (1) WO2000061580A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430978C (en) 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
MXPA04009541A (es) * 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
JP4676884B2 (ja) 2003-07-24 2011-04-27 第一三共株式会社 シクロヘキサンカルボン酸類
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
WO2005070891A2 (en) 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
CN101039652A (zh) * 2004-08-16 2007-09-19 宝洁公司 2－(氨基或取代的氨基)－5,6－取代的苯酚化合物，包含该化合物的染料组合物以及它们的应用
DE102004041137A1 (de) * 2004-08-25 2006-03-02 Wella Ag o-Aminophenol-Derivate und diese Verbindungen enthaltende Färbemittel
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
US7514460B2 (en) 2004-12-22 2009-04-07 4Sc Ag Benzazole analogues and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
US7931838B2 (en) * 2006-08-31 2011-04-26 Virginia Tech Intellectual Properties, Inc. Method for making oriented single-walled carbon nanotube/polymer nano-composite membranes
AU2008319366B2 (en) * 2007-10-29 2012-03-01 Amgen Inc. Benzomorpholine derivatives and methods of use
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
EP4091624A1 (de) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin-analoga und verwendungen davon
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
EP3681900A4 (de) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. Opioidagonistpeptide und verwendungen davon
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP3876939A4 (de) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazolderivate und 7-aza-benzothiazol-derivate als inhibitoren der janus-kinase-2 und verwendungen davon
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
EP4267574B1 (de) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxybenzimidazole und azabenzimidazole als jak2-inhibitoren
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9801716A (es) * 1995-08-30 1998-05-31 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
KR20010042614A (ko) * 1998-04-10 2001-05-25 윌리암스 로저 에이 비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체
WO2000049005A1 (en) * 1999-02-16 2000-08-24 Aventis Pharma Limited Bicyclic compounds and their use as integrin receptor ligands

Also Published As

Publication number Publication date
US20020173506A1 (en) 2002-11-21
EP1183254A1 (de) 2002-03-06
SK14372001A3 (sk) 2002-06-04
EP1183254B1 (de) 2005-01-12
HRP20010732A2 (en) 2002-12-31
BG106083A (en) 2002-05-31
CZ20013661A3 (cs) 2002-01-16
TR200102959T2 (tr) 2002-04-22
HK1044937A1 (zh) 2002-11-08
PL351433A1 (en) 2003-04-22
DE60017389D1 (de) 2005-02-17
AU769554B2 (en) 2004-01-29
IL145748A0 (en) 2002-07-25
HUP0200803A3 (en) 2002-12-28
NO20014951L (no) 2001-12-11
NO20014951D0 (no) 2001-10-11
KR20010110750A (ko) 2001-12-13
IL145748A (en) 2007-02-11
ES2231179T3 (es) 2005-05-16
BR0010599A (pt) 2002-02-13
HUP0200803A2 (hu) 2002-07-29
MXPA01010231A (es) 2003-07-21
CN1350534A (zh) 2002-05-22
WO2000061580A1 (en) 2000-10-19
US6706738B2 (en) 2004-03-16
DE60017389T2 (de) 2006-03-02
ATE286896T1 (de) 2005-01-15
CA2369728A1 (en) 2000-10-19
AU3981600A (en) 2000-11-14
NZ514602A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
ATE286896T1 (de) Substituierte bicyclische heteroaryl-verbindungen als integrin antagonisten
DE3481841D1 (de) Bicyclische kondensierte n-(4-piperidinyl)-2-imidazolamin-derivate.
MY135686A (en) Indole derivatives useful as histamine h3 antagonists
UA41901C2 (uk) Сіль малеїнової кислоти 5-[4-[2-(n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2, 4-діону або її таутомерна форма і/або її фармацевтично прийнятний сольват, спосіб її одержання, фармацевтична композиція і спосіб лікування і/або профілактики гіперглікемії, гіперліпідемії, гіпертонії, серцево-судинних захворювань і деяких захворювань, пов'язаних з вживанням їжі.
DK1392306T3 (da) Substituerede tetrahydroisoquinoliner til anvendelse i behandlingen af inflammatoriske sygdomme
ATE212991T1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
NZ221112A (en) Bicyclic aromatic compounds and pharmaceutical compositions
FI942381A0 (fi) Aryylisubstituoituja heterosyklisiä yhdisteitä
ATE421958T1 (de) Substituierte bizyclische verbindungen
DK1153017T3 (da) Bicykliske forbindelser og deres anvendelse som integrinreceptorligander
MY132062A (en) Apolipoprotein-b synthesis inhibitors
Kitamura et al. Orally active GPIIb/IIIa antagonists: synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4-[(2S)-2-(4-amidinobenzoylamino)-3-(4-methoxyphenyl) propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic acid
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
DE69221634D1 (de) 5-Piperazinylalkyl)-1,5-Benzothiazepinone verwendbar als Calciumantagonisten
DE69824756D1 (de) Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen,hypolipidämischen und antihypertensiven eigenschaften
AR002715A1 (es) Derivados de piperazina y piperazinona heterociclos substituidos particularmente utiles como antagonistas de los receptores de taquikinina,composicion farmaceutica que incluye uno de dichos derivados, uso de dichos compuestos en la preparacion de las composiciones y procedimiento para la preparacion de los derivados
DE68916685D1 (de) Mevalonolactone vom Typ Pyrazolopyridin.
YU71501A (sh) Supstituisana biciklična heteroaril jedinjenja kao antagonisti integrina
ATE228134T1 (de) Kondensierte pyrimidinderivate und diese enthaltende pharmazeutische zubereitungen
ATE109485T1 (de) Derivate von n-(vincristinyl-23) und n- (noranhydro-5-vinblastinyl-23) von amino-1- methylphosphonsäure, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
MX9703074A (es) Inhibidores de sintesis de apoliproteina-b.